factually
Index/Topics/CLARITY-AD Trial

CLARITY-AD Trial

Clinical trial for lecanemab

Fact-Checks

2 results
Jan 12, 2026

How do anti‑amyloid monoclonal antibodies differ in mechanism, efficacy, and safety (lecanemab vs donanemab vs aducanumab)?

Anti‑amyloid monoclonal antibodies differ in what forms of Aβ they bind, how much they lower brain amyloid and downstream biomarkers, and in clinical benefit versus risk balance: lecanemab targets sol...

Jan 7, 2026

How clinically meaningful are the cognitive changes seen with lecanemab and donanemab in real‑world patients?

The randomized trials of lecanemab and donanemab showed statistically significant slowing of cognitive and functional decline over 18 months, but the absolute differences were small versus placebo and...